CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing a novel drug candidate, EV100, to enhance the healing of chronic wounds in diabetic patients. Utilizing genetically modified bacteria, it aims to deliver therapeutic proteins directly to wounds, improving healing efficiency and reducing healthcare costs.
The objective of the project is to develop the EV100 drug candidate to heal chronic wounds in patients with diabetes in a better, faster, and cheaper manner than any method available today.We have chosen to target wounds in patients with diabetes, due to a large unmet medical need in this group.
Today, 18% of people with diabetes have a chronic wound which translates into at least 6 million people in Europe alone.
One of the complications of diabetes, diabetic foot ulcers (DFUs) often result in…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
